Free Trial
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals logo
$7.57 +0.08 (+1.01%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$7.56 0.00 (-0.01%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Key Stats

Today's Range
$7.45
$7.61
50-Day Range
$7.48
$8.64
52-Week Range
$5.20
$10.67
Volume
1.01 million shs
Average Volume
1.37 million shs
Market Capitalization
$1.02 billion
P/E Ratio
27.02
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Buy

Company Overview

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

AUPH MarketRank™: 

Aurinia Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 1150th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aurinia Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Aurinia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurinia Pharmaceuticals is 27.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurinia Pharmaceuticals is 27.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

  • Price to Book Value per Share Ratio

    Aurinia Pharmaceuticals has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Aurinia Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    8.82% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Aurinia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aurinia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.82% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Aurinia Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    34 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

  • Read more about Aurinia Pharmaceuticals' insider trading history.
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

Aurinia Pharmaceuticals (AUPH) Gets a Buy from TD Cowen
Aurinia Pharmaceuticals Inc News (AUPH) - Investing.com
Banks aren’t ready for this altcoin—are you?
Want to see why we believe this could be the next evolution of financial infrastructure? The old financial system is showing cracks—and this altcoin might be ready to take its place
AUPH - Aurinia Pharmaceuticals Inc News - Morningstar
See More Headlines

AUPH Stock Analysis - Frequently Asked Questions

Aurinia Pharmaceuticals' stock was trading at $8.98 at the start of the year. Since then, AUPH shares have decreased by 15.7% and is now trading at $7.5660.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its quarterly earnings data on Monday, May, 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.08. The biotechnology company had revenue of $62.47 million for the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a net margin of 16.11% and a trailing twelve-month return on equity of 14.27%.
Read the conference call transcript
.

Top institutional shareholders of Aurinia Pharmaceuticals include City Center Advisors LLC (0.02%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends
.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/12/2025
Today
7/03/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.50
High Stock Price Target
$13.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+52.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
27.02
Forward P/E Ratio
68.78
P/E Growth
N/A
Net Income
$5.75 million
Pretax Margin
16.91%

Debt

Sales & Book Value

Annual Sales
$235.13 million
Cash Flow
$0.31 per share
Price / Cash Flow
24.28
Book Value
$2.68 per share
Price / Book
2.82

Miscellaneous

Free Float
118,621,000
Market Cap
$1.02 billion
Optionable
Optionable
Beta
1.16

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:AUPH) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners